Buy Lucius Niraparib online
Buy Lucius Niraparib online

Buy Lucius Niraparib online

MYR 866.66

400+ terjual
Harga Promosi

Farmasi fizikal Hong Kong dengan jaminan produk tulen 100%

Sorotan Produk

Indicated as maintenance treatment for advanced ovarian, fallopian tube, or primary peritoneal cancer that has responded to platinum-based chemotherapy, particularly in patients with HRD-positive disease or a germline BRCA mutation.

Jaminan Perkhidmatan

Penghantaran Rentas SempadanFarmasi BerlesenDisemak Ahli FarmasiJaminan Ketulenan

Spesifikasi

Spesifikasi
100mg*30 tablets
Pengilang
Lucius Pharmaceuticals
Penghantaran
Hong Kong

10000 in stock

Category: Tags: , , Brand:

Maklumat Produk

Nama Inggeris
Niraparib
Nama Generik
Niraparib

Spesifikasi

Spesifikasi
100mg*30 tablets
Pengilang
Lucius Pharmaceuticals
Penghantaran
Hong Kong

Butiran Penuh

Indikasi

Indicated as maintenance treatment for advanced ovarian, fallopian tube, or primary peritoneal cancer that has responded to platinum-based chemotherapy, particularly in patients with HRD-positive disease or a germline BRCA mutation.

Mekanisme Tindakan

PARP ， PARP-1 PARP-2， DNA ， PARP PARP-DNA ， DNA BRCA1/2 BRCA1/2 HRD BRCA1/2 ，

Farmakologi

12.1 Mekanisme Tindakan PARP ， PARP-1 PARP-2， DNA ， PARP PARP-DNA ， DNA BRCA1/2 BRCA1/2 HRD BRCA1/2 ，

Dos dan Cara Penggunaan

2.1 BRCA2 AKEEGA mCSPC [ (14.1)] BRCA AKEEGA mCRPC [ (14.2)] FDA ， BRCA2 (BRCA2m) (mCSPC) AKEEGA 200 mg /1000 mg ， 5 mg ， BRCA BRCAm mCRPC AKEEGA 200 /1,

Langkah Berjaga-jaga

5.1 / AKEEGA / (MDS/AML) AMPLITUDE MAGNITUDE ， AKEEGA ，MDS AML 0.6% (2/347) 0.5% (1/212)， AKEEGA MDS/ AML ， / DNA MDS/AML ， MDS/AML， AKEEGA

Interaksi Ubat

7.1 AKEEGA CYP3A4 CYP3A4 [ (12.3)] CYP3A4 CYP3A4 [ (12.3)]， 7.2 AKEEGA CYP2D6 ， CYP2D6 ，

Kesan Sampingan

/ [ Langkah Berjaga-jaga(5.1)] [ Langkah Berjaga-jaga(5.2)] [ Langkah Berjaga-jaga(5.3)] [ Langkah Berjaga-jaga(5.4)] [ Langkah Berjaga-jaga(5.5)] [ Langkah Berjaga-jaga(5.6)] 223 [ Langkah Berjaga-jaga(5.7)] [ Langkah Berjaga-jaga(5.8)] 6.1

Penyimpanan

AKEEGA® AKEEGA 50 /500 ， ， ， “N 50 A”， 60 NDC 57894-050-60 AKEEGA 100 /500 ， ， ， “N 50 A”，

Package Insert

Ingredients

11 AKEEGA® ADP- PARP 2-{4-[(3S)- -3- ] }-2H- 7- 4- 1:1:1 C₂₆H₃₀N₄O₅S， 510.61 g/mol

Indications

Indicated as maintenance treatment for advanced ovarian, fallopian tube, or primary peritoneal cancer that has responded to platinum-based chemotherapy, particularly in patients with HRD-positive disease or a germline BRCA mutation.

Dos dan Cara Penggunaan

2.1 BRCA2 AKEEGA mCSPC [ (14.1)] BRCA AKEEGA mCRPC [ (14.2)] FDA ， BRCA2 (BRCA2m) (mCSPC) AKEEGA 200 mg /1000 mg ， 5 mg ， BRCA BRCAm mCRPC AKEEGA 200 /1,

Kesan Sampingan

/ [ Langkah Berjaga-jaga(5.1)] [ Langkah Berjaga-jaga(5.2)] [ Langkah Berjaga-jaga(5.3)] [ Langkah Berjaga-jaga(5.4)] [ Langkah Berjaga-jaga(5.5)] [ Langkah Berjaga-jaga(5.6)] 223 [ Langkah Berjaga-jaga(5.7)] [ Langkah Berjaga-jaga(5.8)] 6.1

Precautions

5.1 / AKEEGA / (MDS/AML) AMPLITUDE MAGNITUDE ， AKEEGA ，MDS AML 0.6% (2/347) 0.5% (1/212)， AKEEGA MDS/ AML ， / DNA MDS/AML ， MDS/AML， AKEEGA

Use in Pregnancy and Lactation

8.1 AKEEGA Mekanisme Tindakan[ (12.1)]，AKEEGA AKEEGA / - ， ， [ Langkah Berjaga-jaga (5.2) (13.1)] Mekanisme Tindakan ，

Interaksi Ubat

7.1 AKEEGA CYP3A4 CYP3A4 [ (12.3)] CYP3A4 CYP3A4 [ (12.3)]， 7.2 AKEEGA CYP2D6 ， CYP2D6 ，

Clinical Pharmacology

12 12.1 Mekanisme Tindakan PARP ， PARP-1 PARP-2， DNA ， PARP PARP-DNA ， DNA BRCA1/2 BRCA1/2 HRD BRCA1/2 ， ， ， 17α- /C17,20-

Clinical Studies

14 14.1 BRCA2 (mCSPC) AKEEGA AMPLITUDE (NCT04497844) ， 696 (HRR) (HRRm) mCSPC ， 1:1 ， 200 mg 1000 mg (n=348) (n=348) 5 mg， 14 (ADT) mCSPC ， 45 6 6 ADT HRR BRCA2 CDK12

Penyimpanan

AKEEGA® AKEEGA 50 /500 ， ， ， “N 50 A”， 60 NDC 57894-050-60 AKEEGA 100 /500 ， ， ， “N 50 A”，

Ulasan Produk (17)

Filter: All Reviews
4.8★★★★★
+o***e· 3 weeks ago
★★★★
+t***3· 1 months ago
Pembelian Disahkan
★★★★★

Penerangan produk

Indikasi

Indicated as maintenance treatment for advanced ovarian, fallopian tube, or primary peritoneal cancer that has responded to platinum-based chemotherapy, particularly in patients with HRD-positive disease or a germline BRCA mutation.

Mekanisme Tindakan

PARP ， PARP-1 PARP-2， DNA ， PARP PARP-DNA ， DNA BRCA1/2 BRCA1/2 HRD BRCA1/2 ，

Farmakologi

12.1 Mekanisme Tindakan PARP ， PARP-1 PARP-2， DNA ， PARP PARP-DNA ， DNA BRCA1/2 BRCA1/2 HRD BRCA1/2 ，

Dos dan Cara Penggunaan

2.1 BRCA2 AKEEGA mCSPC [ (14.1)] BRCA AKEEGA mCRPC [ (14.2)] FDA ， BRCA2 (BRCA2m) (mCSPC) AKEEGA 200 mg /1000 mg ， 5 mg ， BRCA BRCAm mCRPC AKEEGA 200 /1,

Langkah Berjaga-jaga

5.1 / AKEEGA / (MDS/AML) AMPLITUDE MAGNITUDE ， AKEEGA ，MDS AML 0.6% (2/347) 0.5% (1/212)， AKEEGA MDS/ AML ， / DNA MDS/AML ， MDS/AML， AKEEGA

Interaksi Ubat

7.1 AKEEGA CYP3A4 CYP3A4 [ (12.3)] CYP3A4 CYP3A4 [ (12.3)]， 7.2 AKEEGA CYP2D6 ， CYP2D6 ，

Kesan Sampingan

/ [ Langkah Berjaga-jaga(5.1)] [ Langkah Berjaga-jaga(5.2)] [ Langkah Berjaga-jaga(5.3)] [ Langkah Berjaga-jaga(5.4)] [ Langkah Berjaga-jaga(5.5)] [ Langkah Berjaga-jaga(5.6)] 223 [ Langkah Berjaga-jaga(5.7)] [ Langkah Berjaga-jaga(5.8)] 6.1

Penyimpanan

AKEEGA® AKEEGA 50 /500 ， ， ， “N 50 A”， 60 NDC 57894-050-60 AKEEGA 100 /500 ， ， ， “N 50 A”，